A systematic review of quality and cost–effectiveness derived from Markov models evaluating smoking cessation interventions in patients with chronic obstructive pulmonary disease

References:

• Smoking USSGsACo. Smoking and health: report of the advisory committee to the Surgeon General of the public health service. (US Dept. of Health, Education, and Welfare, Public Health Service;for sale by the Superintendent of Documents, US Govt. Print. Off.). 1964
   Google Scholar
• National Center for Chronic Disease Prevention, Health Promotion Office on Smoking and Health. Reports of the Surgeon General. In: The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General. Centers for Disease Control and Prevention. Atlanta, GA, USA; 2014
   Google Scholar
• In: U.S. Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA, USA; 2004
   Google Scholar
• Kirsch F, Teuner CM, Menn P, Leidl R. [Costs of illness for asthma and COPD in adults in Germany]. Gesundheitswesen 2013;75(7):413-23
   PubMedGoogle Scholar
• Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002;166(5):675-9
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Buhl R, Criee CP, et al. [Guidelines for the diagnosis and therapy of COPD issued by Deutsche Atemwegsliga and Deutsche Gesellschaft fur Pneumologie und Beatmungsmedizin]. Pneumologie 2007;61(5):e1-40
   Google Scholar
• Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187(4):347-65
   PubMed Web of Science ®Google Scholar
• Menn P, Leidl R, Holle R. A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease. Pharmacoeconomics 2012;30(9):825-40
   PubMed Web of Science ®Google Scholar
• Philips Z, Bojke L, Sculpher M, et al. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 2006;24(4):355-71
   PubMed Web of Science ®Google Scholar
• Goeree R, He J, O’Reilly D, et al. Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application. Clinicoecon Outcomes Res 2011;3:89-104
   PubMedGoogle Scholar
• Becker C, Langer A, Leidl R. The quality of three decision-analytic diabetes models: a systematic health economic assessment. Expert Rev Pharmacoecon Outcomes Res 2011;11(6):751-62
   PubMed Web of Science ®Google Scholar
• Hatz MH, Leidl R, Yates NA, Stollenwerk B. A systematic review of the quality of economic models comparing thrombosis inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Pharmacoeconomics 2014;32(4):377-93
   PubMed Web of Science ®Google Scholar
• Jaime Caro J, Eddy DM, Kan H, et al. Questionnaire to assess relevance and credibility of modeling studies for informing health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health 2014;17(2):174-82
   PubMed Web of Science ®Google Scholar
• Vemer P, Rutten-van Molken MP. Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries. Value Health 2010;13(2):230-41
   PubMed Web of Science ®Google Scholar
• Hoogendoorn M, Feenstra TL, Asukai Y, et al. Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios. Value Health 2014;17(5):525-36
   PubMed Web of Science ®Google Scholar
• Hoogendoorn M, Feenstra TL, Hoogenveen RT, Rutten-van Molken MP. Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax 2010;65(8):711-18
   PubMed Web of Science ®Google Scholar
• Hoogendoorn M, Rutten-van Molken MP, Hoogenveen RT, et al. Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease. Value Health 2011;14(8):1039-47
   PubMed Web of Science ®Google Scholar
• Hoogendoorn M, Rutten-van Molken MP, Hoogenveen RT, et al. A dynamic population model of disease progression in COPD. Eur Respir J 2005;26(2):223-33
   PubMedGoogle Scholar
• Lock K, Wilson K, Murphy D, Riesco JA. A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother 2011;12(17):2613-26
   PubMed Web of Science ®Google Scholar
• Hurley SF, Matthews JP. Cost-effectiveness of the Australian National Tobacco Campaign. Tob Control 2008;17(6):379-84
   PubMed Web of Science ®Google Scholar
• Howard P, Knight C, Boler A, Baker C. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers. Pharmacoeconomics 2008;26(6):497-511
   PubMed Web of Science ®Google Scholar
• Lang K, Wasem J, Aidelsburger P. Kosteneffektivität der Nikotinersatztherapie bei Patienten mit chronisch obstruktiver Lungenerkrankung - ein entscheidungsanalytisches Model. PharmacoEconomics 2008;6(2):111-23
   Google Scholar
• Chandra K, Blackhouse G, McCurdy BR, et al. Cost-effectiveness of interventions for chronic obstructive pulmonary disease (COPD) using an Ontario policy model. Ont Health Technol Assess Ser 2012;12(12):1-61
   Google Scholar
• Atsou K, Chouaid C, Hejblum G. Simulation-based estimates of effectiveness and cost-effectiveness of smoking cessation in patients with chronic obstructive pulmonary disease. PLoS One 2011;6(9):e24870
   PubMed Web of Science ®Google Scholar
• Faulkner MA, Lenz TL, Stading JA. Cost-effectiveness of smoking cessation and the implications for COPD. Int J Chron Obstruct Pulmon Dis 2006;1(3):279-87
   PubMedGoogle Scholar
• Welte R, Feenstra T, Jager H, Leidl R. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 2004;22(13):857-76
   PubMed Web of Science ®Google Scholar
• Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004;8(36): iii-iv, ix-xi 1-158
   PubMed Web of Science ®Google Scholar
• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Revised 2011
   Google Scholar
• Scanlon PD, Connett JE, Waller LA, et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000;161(2 Pt 1):381-90
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994;272(19):1497-505
   PubMed Web of Science ®Google Scholar
• Sundblad BM, Larsson K, Nathell L. High rate of smoking abstinence in COPD patients: smoking cessation by hospitalization. Nicotine Tob Res 2008;10(5):883-90
   PubMedGoogle Scholar
• Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004(3):CD000146
   PubMedGoogle Scholar
• Hurley SF, Matthews JP. The Quit Benefits Model: a Markov model for assessing the health benefits and health care cost savings of quitting smoking. Cost Eff Resour Alloc 2007;5:2
   PubMedGoogle Scholar
• Menn P, Holle R. Comparing three software tools for implementing markov models for health economic evaluations. Pharmacoeconomics 2009;27(9):745-53
   PubMedGoogle Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363(12):1128-38
   PubMed Web of Science ®Google Scholar
• Bolin K. Economic evaluation of smoking-cessation therapies: a critical and systematic review of simulation models. Pharmacoeconomics 2012;30(7):551-64
   PubMedGoogle Scholar
• Getsios D, Marton JP, Revankar N, et al. Smoking cessation treatment and outcomes patterns simulation: a new framework for evaluating the potential health and economic impact of smoking cessation interventions. Pharmacoeconomics 2013;31(9):767-80
   PubMed Web of Science ®Google Scholar
• Ethgen O, Standaert B. Population- versus cohort-based modelling approaches. Pharmacoeconomics 2012;30(3):171-81
   PubMed Web of Science ®Google Scholar
• Nides M, Glover ED, Reus VI, et al. Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am J Health Behav 2008;32(6):664-75
   PubMed Web of Science ®Google Scholar
• Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2002(1):CD000031
   Google Scholar
• Feenstra TL, Hamberg-van Reenen HH, Hoogenveen RT, Rutten-van Molken MP. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. Value Health 2005;8(3):178-90
   PubMed Web of Science ®Google Scholar
• Reviews UoYCf, Dissemination, Akers J. Systematic reviews: CRD’s guidance for undertaking reviews in health care (Centre for Reviews and Dissemination). 2009
   Google Scholar
• Boland M, Tsiachristas A, Kruis AL, et al. Are GOLD ABCD groups better associated with health status and costs than GOLD 1234 grades? A cross-sectional study. Prim Care Respir J 2014;23(1):30-7
   PubMedGoogle Scholar
• Geldmacher H, Biller H, Herbst A, et al. [The prevalence of chronic obstructive pulmonary disease (COPD) in Germany. Results of the BOLD study]. Dtsch Med Wochenschr 2008;133(50):2609-14
   PubMedGoogle Scholar
• van Boven JF, Vegter S, van der Molen T, Postma MJ. COPD in the working age population: the economic impact on both patients and government. COPD 2013;10(6):629-39
   PubMedGoogle Scholar
• Nielsen R, Johannessen A, Benediktsdottir B, et al. Present and future costs of COPD in Iceland and Norway: results from the BOLD study. Eur Respir J 2009;34(4):850-7
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG; The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PLoS Med 2009;6(7):e1000097
   PubMed Web of Science ®Google Scholar